--- title: "Seres Therapeutics (MCRB) stock: news and investor profile" url: "https://aibio.space/companies/seres-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Seres Therapeutics, Inc. (NASDAQ: MCRB), United States. The directory classifies it as Biotechnology." --- MCRB Seres Therapeutics, Inc. NASDAQ · United States # Seres Therapeutics (MCRB) news Top story · Aug 4, 2026 · SEC filing 8-K ## [Seres Therapeutics signs a material agreement](https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/d133274d8k.htm) Lease Amendment and Termination Agreement On July 31, 2026 (the “Execution Date”), Seres Therapeutics, Inc. Source: [8-K filed Aug 4, 2026 on SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/d133274d8k.htm) ## Latest Seres Therapeutics news We have not published a story on Seres Therapeutics yet. When there is news, it will appear here. ## Seres Therapeutics at a glance - **Ticker**: MCRB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $15.6 million ### Related companies - [Rani Therapeutics Holdings](https://aibio.space/companies/rani-therapeutics/) NASDAQ: RANI - [Life Stem Genetics](https://aibio.space/companies/life-stem-genetics/) OTC: LIFS - [Monopar Therapeutics](https://aibio.space/companies/monopar-therapeutics/) NASDAQ: MNPR - [Zura Bio](https://aibio.space/companies/zura-bio/) NASDAQ: ZURA - [Candel Therapeutics](https://aibio.space/companies/candel-therapeutics/) NASDAQ: CADL - [MBX Biosciences](https://aibio.space/companies/mbx-biosciences/) NASDAQ: MBX - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) NASDAQ: FDMT - [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) NASDAQ: IPSC ### Also on NASDAQ - [Absci](https://aibio.space/companies/absci/) ABSI - [Glucotrack](https://aibio.space/companies/glucotrack/) GCTK - [Acumen Pharmaceuticals](https://aibio.space/companies/acumen-pharmaceuticals/) ABOS - [AETHLON MEDICAL INC](https://aibio.space/companies/aethlon-medical/) AEMD - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) ELVN - [DELCATH SYSTEMS, INC.](https://aibio.space/companies/delcath-systems/) DCTH ## Seres Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$789,000](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/) | [$0](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/) | | Research and development | [$49.1 million](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/) | [$64.6 million](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/) | | Net income (loss) | [$5.7 million](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/) | [$136,000](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/) | | Cash from operations | [$1.1 million](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/) | [-$148.6 million](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/) | | Cash and equivalents | [$45.8 million](https://www.sec.gov/Archives/edgar/data/1609809/000119312526334174/) | [$30.8 million](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $15.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Seres Therapeutics What is the ticker symbol of Seres Therapeutics? Seres Therapeutics, Inc. trades under the ticker MCRB on NASDAQ. Where is Seres Therapeutics listed? Seres Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1S90; LS:A413XF. What is the SEC CIK of Seres Therapeutics? The SEC Central Index Key (CIK) for Seres Therapeutics, Inc. is 1609809. Its filings are on SEC EDGAR. How many shares does Seres Therapeutics have outstanding? 9,941,261 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Seres Therapeutics listed under? Our directory records Seres Therapeutics, Inc. under United States. What does Seres Therapeutics do? Our directory classifies Seres Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Seres Therapeutics? The ISIN recorded for Seres Therapeutics, Inc. is US81750R2013. Does aibio.space cover Seres Therapeutics? aibio.space lists Seres Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Seres Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was Seres Therapeutics's revenue last year? $789,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Seres Therapeutics profitable? Seres Therapeutics, Inc. reported net income of $5.7 million for the fiscal year ended Dec 31, 2025, and generated $1.1 million of cash from operations, per its annual report to the SEC. How much does Seres Therapeutics spend on research and development? $49.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Seres Therapeutics have? $15.6 million in cash at Jun 30, 2026, per its 10-Q. What is Seres Therapeutics's market cap? We do not publish live share prices. In its annual report, Seres Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $71.9 million as of Jun 30, 2025. Is Seres Therapeutics a smaller reporting company? SEC records list Seres Therapeutics, Inc.'s filer category as: Non-accelerated filer
Smaller reporting company. ## Investor discussion: Seres Therapeutics Members talk about Seres Therapeutics (MCRB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Seres Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-04 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/d133274d8k.htm) 2. 2025-05-07 Listings Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1609809/000119312525114430/d915177dex991.htm) 3. 2025-04-22 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1609809/000119312525089189/d97309d8k.htm) 4. 2025-04-14 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1609809/000119312525080185/d935169d8k.htm) 5. 2025-03-13 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1609809/000095017025038441/mcrb-20250313.htm) 6. 2025-03-03 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1609809/000095017025030842/mcrb-20250303.htm) 7. 2024-11-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1609809/000119312524256654/d912869dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MCRB on TradingView](https://www.tradingview.com/symbols/NASDAQ-MCRB/). ## SEC filings and registration - **SEC name**: Seres Therapeutics, Inc. - **CIK**: 1609809 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MCRB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 200 SIDNEY STREET, CAMBRIDGE, MA, 02139 - **Phone**: 617 945 9626 - **Shares outstanding**: 9,941,261 as of 2026-08-03 (10-Q filed 2026-08-05) - **Former names**: Seres Therapeutics, Inc.; Seres Health, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [S-3](https://www.sec.gov/Archives/edgar/data/1609809/000119312526349330/d215784ds3.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1609809/000119312526334174/mcrb-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/d124829d8k.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/d133274d8k.htm) filed 2026-08-04 - [424B5](https://www.sec.gov/Archives/edgar/data/1609809/000119312526332730/d141279d424b5.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1609809/000119312526298525/d100733d8k.htm) filed 2026-07-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1609809/000119312526298005/d130829d8k.htm) filed 2026-07-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1609809/000119312526258366/d156701d8k.htm) filed 2026-06-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001609809), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Seres Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MCRB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Seres Therapeutics, Inc. - **Ticker**: MCRB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US81750R2013 - **Other listed symbols**: GETTEX:1S90; LS:A413XF - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MCRB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/seres-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Seres Therapeutics (MCRB) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/seres-therapeutics/